Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ANPEP | P15144 | 2/20 | 0.42 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.42 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.42 |
| ▸ | PNP | P00491 | 1/20 | 0.41 |
| ▸ | ACP3 | P15309 | 2/20 | 0.39 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.38 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.38 |
| ▸ | CFTR | P13569 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL233490 | 0.79 | FDPS (0.56) | FDPSANPEPERAP1ERAP2ACP3 | |
| Pyrophosphoric Acid SCHEMBL866450 | 0.78 | FDPS (0.51) | FDPSALDH1A1ANPEPERAP1ERAP2 | |
| Phosphoric Acid SCHEMBL28335107 | 0.77 | FDPS (0.58) | FDPSALDH1A1ACP3 | |
| SCHEMBL27708637 | 0.76 | FDPS (0.41) | FDPSALDH1A1CFTR | |
| SCHEMBL234864 | 0.75 | CYP3A4 (0.53) | FDPSMEN1ALDH1A1KMT2A | |
| SCHEMBL27463949 | 0.73 | KMT2A (0.49) | MEN1ALDH1A1KMT2AS1PR3 | |
| SCHEMBL20068080 | 0.73 | SRC (0.44) | MEN1ALDH1A1KMT2AACP3S1PR2 | |
| SCHEMBL27811913 | 0.73 | ACP3 (0.68) | ACP3 | |
| Phosphoric Acid SCHEMBL28361006 | 0.73 | LIPG (0.53) | FDPSALDH1A1S1PR2S1PR4S1PR1 | |
| SCHEMBL11492465 | 0.72 | FDPS (0.53) | FDPSALDH1A1ANPEPERAP1ERAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210130377-A1 | BETA-PHOSPHONYL-ENAMINE DERIVATIVE AND PREPARATION METHOD THEREFOR | SOOCHOW UNIVERSITY (CN) | 2021-05-06 | — | — | US | disclosed |
| US-20210130376-A1 | BETA-AMINO PHOSPHONIC ACID DERIVATIVE AND PREPARATION METHOD THEREFOR | SOOCHOW UNIVERSITY (CN) | 2021-05-06 | — | — | US | disclosed |
| CN-108864185-B | β -phosphonoenamine derivatives and process for their preparation | 苏州大学 | 2020-05-08 | — | — | CN | disclosed |
| CN-108727428-B | β -aminophosphonic acid derivatives and process for their preparation | 苏州大学 | 2020-05-08 | — | — | CN | disclosed |
| WO-2020010586-A1 | β-AMINO PHOSPHONIC ACID DERIVATIVE AND PREPARATION METHOD THEREFOR | 苏州大学张家港工业技术研究院 | 2020-01-16 | — | — | WO | disclosed |
| WO-2020010587-A1 | β-PHOSPHONYL-ENAMINE DERIVATIVE AND PREPARATION METHOD THEREFOR | 苏州大学张家港工业技术研究院 | 2020-01-16 | — | — | WO | disclosed |
| EP-2097387-B1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2016-05-04 | — | — | EP | disclosed |
| US-8829036-B2 | Heterocyclic aspartyl protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-09-09 | — | — | US | disclosed |
| US-8778980-B2 | Heterocyclic aspartyl protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20130018066-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | Schering Corporation & Pharmacopeia Drug Discovery Inc. (US) | 2013-01-17 | — | — | US | disclosed |
| EP-2097387-A2 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION (US) | 2009-09-09 | — | — | EP | disclosed |
| EP-1838304-B1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | SCHERING CORP (US) | 2009-08-19 | — | — | EP | disclosed |
| US-20090111919-A1 | pyrogenic alumina particles of given surface area, that has been surface treated with organophosphonic acids and hydroxycarboxylic acids; improve the mechanical properties of a melamine-based laminate for use as protective wear resistant coating on furniture, floors; high solids | EVONIK DEGUSSA GMBH (DE) | 2009-04-30 | — | — | US | disclosed |
| EP-1987095-A1 | ALUMINIUM OXIDE-CONTAINING DISPERSION | Evonik Degussa GmbH (DE) | 2008-11-05 | — | — | EP | disclosed |
| WO-2008103351-A2 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION (US) | 2008-08-28 | — | — | WO | disclosed |
| US-20080200445-A1 | Use in treatment of cardiovascular diseases, cognitive and neurodegenerative diseases, inhibitors of Human Immunodeficiency Virus, plasmepsins, cathepsin D and protozoal enzymes; 4-imidazolidinone, 5-(3'-chloro[1,1'-biphenyl]-3-yl)-5-cyclopropyl-2-imino-3-(2,2,2-trifluoroethyl)-, for example | SCHERING CORPORATION & PHARMACOPEIA DRUG DISCOVERY, INC. | 2008-08-21 | — | — | US | disclosed |
| EP-1838304-A2 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION (US) | 2007-10-03 | — | — | EP | disclosed |
| WO-2007096226-A1 | ALUMINIUM OXIDE-CONTAINING DISPERSION | EVONIK DEGUSSA GMBH (DE) | 2007-08-30 | — | — | WO | disclosed |
| WO-2006065277-A2 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION (US) | 2006-06-22 | — | — | WO | disclosed |
| US-20060111370-A1 | Heterocyclic aspartyl protease inhibitors | SCHERING CORPORATION | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111370-A1 | Heterocyclic aspartyl protease inhibitors | CHRM1, CHRM2, PRSS1 | FDPS 4342/4885MEN1 1192/4885ALDH1A1 4505/4885 |
| US-20210130377-A1 | BETA-PHOSPHONYL-ENAMINE DERIVATIVE AND PREPARATION METHOD THEREFOR | PHOSPHO1, SLC6A12, PKLR | FDPS 2568/4885MEN1 32/4885ALDH1A1 4506/4885 |
| US-20080200445-A1 | Use in treatment of cardiovascular diseases, cognitive and neurodegenerative diseases, inhibitors of Human Immunodeficiency Virus, plasmepsins, cathepsin D and protozoal enzymes; 4-imidazolidinone, 5-(3'-chloro[1,1'-biphenyl]-3-yl)-5-cyclopropyl-2-imino-3-(2,2,2-trifluoroethyl)-, for example | CTSZ, CTSL, PRSS1 | FDPS 3730/4885MEN1 4299/4885ALDH1A1 4571/4885 |
| US-20210130376-A1 | BETA-AMINO PHOSPHONIC ACID DERIVATIVE AND PREPARATION METHOD THEREFOR | AADAT, PHYKPL, AASDHPPT | FDPS 1670/4885MEN1 614/4885ALDH1A1 2879/4885 |
| US-20130018066-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | CHRM1, CHRM2, PRSS1 | FDPS 4342/4885MEN1 1192/4885ALDH1A1 4505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.